Good morning :)
Place Order
Add to Watchlist

Vivo Bio Tech Ltd

VIVOBIOT

Vivo Bio Tech Ltd

VIVOBIOT
Health CareBiotechnology
SmallcapWith a market cap of ₹57 cr, stock is ranked 3,407
High RiskStock is 3.72x as volatile as Nifty
38.660.62% (-0.24)
38.660.62% (-0.24)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareBiotechnology
SmallcapWith a market cap of ₹57 cr, stock is ranked 3,407
High RiskStock is 3.72x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

Avg

Can be considered moderately valued vs the market

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CareBiotechnology
SmallcapWith a market cap of ₹57 cr, stock is ranked 3,407
High RiskStock is 3.72x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
7.731.06
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
50.626.470.53%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Vivo Bio Tech Limited is a biotechnology company that operates as a contract research organization (CRO) offering drug development and discovery services. It offers services in the areas of In vitro, In vivo, toxicity studies etc.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of -4.02%, vs industry avg of 19.21%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.81% to 0.27%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 2.38%, vs industry avg of 1.42%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue29.4734.5347.1355.8455.4051.8651.4952.2745.4951.47
Raw Materialssubtract8.198.6212.6012.4110.909.917.974.934.6525.07
Power & Fuel Costsubtract2.462.912.872.934.695.783.564.273.93
Employee Costsubtract4.345.507.669.5810.008.579.4213.5210.68
Selling & Administrative Expensessubtract6.538.1412.3312.308.7511.789.994.795.03
Operating & Other expensessubtract3.361.330.669.108.54-2.074.362.88-0.10
Depreciation/Amortizationsubtract3.353.904.645.065.175.597.459.279.299.23
Interest & Other Itemssubtract0.471.292.372.643.103.674.277.997.957.72
Taxes & Other Itemssubtract-0.130.330.88-0.42-0.192.942.271.971.541.98
EPS0.962.683.252.023.524.331.591.821.695.01
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CareBiotechnology

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Vivo Bio Tech Ltd22.911.06
Biocon Ltd39.401.590.15%
Panacea Biotec Ltd-2,231.203.09
Hester Biosciences Ltd119.207.430.23%

Price Comparison

Compare VIVOBIOT with any stock or ETF
Compare VIVOBIOT with any stock or ETF
VIVOBIOT
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding42.08%0.00%0.00%0.00%57.92%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

VIVOBIOT has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Corporate
Vivo Bio Tech to convene board meeting

Vivo Bio Tech will hold a meeting of the Board of Directors of the Company on 21 November 2024Powered by Capital Market - Live

1 week agoCapital Market - Live
Earnings
Vivo Bio Tech consolidated net profit rises 1484.85% in the September 2024 quarter

Net profit of Vivo Bio Tech rose 1484.85% to Rs 5.23 crore in the quarter ended September 2024 as against Rs 0.33 crore during the previous quarter ended September 2023. Sales rose 30.02% to Rs 12.04 crore in the quarter ended September 2024 as against Rs 9.26 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales12.049.26 30 OPM %46.4352.48 - PBDT8.162.77 195 PBT5.870.46 1176 NP5.230.33 1485 Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Vivo Bio Tech to hold board meeting

Vivo Bio Tech will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Vivo Bio Tech to convene AGM

Vivo Bio Tech announced that the 37th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Vivo Bio Tech consolidated net profit rises 21.43% in the June 2024 quarter

Net profit of Vivo Bio Tech rose 21.43% to Rs 0.17 crore in the quarter ended June 2024 as against Rs 0.14 crore during the previous quarter ended June 2023. Sales declined 12.52% to Rs 10.13 crore in the quarter ended June 2024 as against Rs 11.58 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales10.1311.58 -13 OPM %43.1438.77 - PBDT2.452.54 -4 PBT0.220.25 -12 NP0.170.14 21 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Vivo Bio Tech announces board meeting date

Vivo Bio Tech will hold a meeting of the Board of Directors of the Company on 10 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live